GSK Ends Flovent Monopoly After Senate Investigation Reveals $367 Million Medicaid Rebate Avoidance
核心洞察
GlaxoSmithKline discontinued its popular asthma inhaler Flovent in December 2023 to avoid paying an estimated $367.6 million in additional Medicaid rebates under new federal anti-price gouging provisions.
The discontinuation forced families to switch to more expensive alternatives, with 36% of families reporting difficulty paying for replacements and 30% struggling with insurance coverage according to a Boston Children's Hospital survey.
Following a two-year Senate investigation led by Sen. Maggie Hassan, GSK agreed to allow competitor Glenmark Specialty SA to sell a lower-cost generic version starting this month.
GlaxoSmithKline has agreed to end its monopoly on a critical pediatric asthma inhaler following a two-year Senate investigation that revealed the pharmaceutical giant discontinued its popular Flovent medication to avoid paying hundreds of millions in Medicaid rebates.
Sen. Maggie Hassan, D-N.H., announced Monday that GSK will allow competitor Glenmark Specialty SA to sell a lower-cost generic inhaler starting this month, providing relief to families who have struggled with expensive alternatives since Flovent's discontinuation in December 2023.
Financial Motivations Behind Discontinuation
Hassan's investigation found that GSK discontinued Flovent HFA to circumvent new federal price limits established under the American Rescue Plan Act of 2021. The company had raised Flovent's price so aggressively over time that it was required to pay nearly 100% of the product's market price back to Medicaid in rebates.
When the ARPA law lifted the 100% cap on rebate obligations starting in 2024, GSK would have owed an additional $367.6 million in Medicaid rebates, prompting the immediate discontinuation of the branded product.
"GSK ended sales of Flovent to avoid paying hundreds of millions in rebates it owed due to the higher costs for inhalers it had charged to Medicaid," Hassan said during an online news conference with reporters.
Impact on Families and Clinical Practice
The discontinuation created significant hardships for families managing pediatric asthma. Flovent had been a go-to treatment for millions of children because its safety profile was well-documented and its metered dose inhaler delivery system was particularly suitable for younger children with smaller lungs.
A survey conducted by Dr. Ashley Saint-Fleur at Boston Children's Hospital revealed the extent of the crisis: 36% of families had difficulty paying for Flovent alternatives, while 30% struggled to get insurance coverage for replacement medications. In one case, parents were forced to cut their 5-year-old's dosage in half after their insurer refused coverage, resulting in the child requiring emergency oxygen treatments.
"No one should have to risk a child's welfare because it can't afford medication," Saint-Fleur said.
The clinical impact was equally severe. More than 90% of surveyed clinicians reported that Flovent's discontinuation had a moderate or severe impact on their practices, with many facing chronic shortages of alternative inhalers or struggling to find age-appropriate treatments for patients.
Patient Stories Highlight Real-World Consequences
Alia Hayes of Hampstead, N.H., described how her young son Burton began experiencing severe coughing fits requiring emergency hospital visits after losing access to Flovent. "My son got exposed to some kind of virus and had this unrelenting cough. I called the sound a barking seal but whatever you called it, it cannot convey the traumatic situation that it creates," Hayes said.
Jackie Larkin of Media, Pennsylvania, faced a different challenge when the alternative to Flovent cost $200 per month for her 3-year-old son James. "It shouldn't be this hard to get your child to breathe," Larkin said.
GSK's Alternative Strategy
Instead of continuing Flovent sales, GSK introduced an authorized generic version through Prasco Laboratories that was marketed as a cost-saving alternative. However, this switch allowed GSK to circumvent federal price limits while creating new barriers for patients.
One pharmacy benefit manager reported that the net cost for the authorized generic was five times higher than Flovent's cost for the average customer by the first half of 2024. Many insurers required prior authorization for the alternative, a requirement that hadn't existed for the original Flovent.
Regulatory Response and Future Protections
The Food and Drug Administration has approved a generic version of Flovent that should restore affordable access to the medication for the approximately 4.6 million children diagnosed with asthma nationwide.
Hassan is working on bipartisan legislation to close the loophole that GSK exploited, though she did not provide specific details about the proposed measures. "Big Pharma needs to understand that they can't price gouge and get away with it," Hassan said.
Company Response
In a statement Monday, GSK said it supported Prasco's decision to offer free inhalers to eligible patients and launched its own program capping out-of-pocket monthly costs for any of its nine inhalers at $35 for eligible patients.
"GSK is strongly committed to supporting patients and developing innovative respiratory medicines. We remain committed to ensuring that innovation and affordability can coexist and are focused on improving health outcomes for patients," the company stated.
The company noted that it is not involved in negotiations over cost or insurance coverage for its authorized generic, as those decisions are made by Prasco Laboratories.
As recently as the latter half of last year, 12% of families reported continuing struggles to obtain proper asthma treatment for children due to cost, availability, or coverage issues, highlighting the ongoing need for accessible pediatric respiratory medications.